Phenotypic Characterization of <i>EIF2AK4</i> Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial HypertensionCharaka Hadinnapola, Taco W. Kuijpers, Stephen Preston et al.|Circulation|2017Cited by 144
Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertensionMark Toshner, Paul A. Corris, Colin Church et al.|European Respiratory Journal|2021Cited by 89
Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single‐arm efficacyMartin R. Wilkins, Sofía S. Villar, Mikel A. McKie et al.|Pulmonary Circulation|2021Cited by 31